# Skye Medicine (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/skye-medicine-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $15M
- Latest round: Seed (Mar 19, 2026)
- Investors on record: 5

## About

Based in Shanghai, China, and founded in 2024, Skye Medicine (Shanghai) Co., Ltd. provides cell immunotherapy research and development for the biotechnology industry. The company builds technical platforms to create in vivo therapies and autologous cell processing methods. The firm currently provides its medical research capabilities to the healthcare sector in China. The Founder is Dr. Wen Wang, who has experience in the clinical development and commercialization of CAR-T cell products. In March 2026, the company raised over CNY 100 million in a seed funding round.

The company works with the healthcare and pharmaceutical sectors to provide cell immunotherapy solutions.

The company generates revenue from the research, development and commercialization of its biological medical products.

The company plans to use the seed funding to research and develop in vivo multi target cell therapy candidates, universal multi-target CAR-T products for autoimmune diseases, and autologous fast-process CAR-T cell therapy solutions.

## Funding rounds

- Seed, Mar 19, 2026, $15M — Hony Capital, Addor Capital, MED-FINE Capital, CS Capital, Suzhou Capital Group

## Investors

- Hony Capital (https://capitalatlas.ai/funds/hony-capital) — Seed
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Seed
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Seed
- CS Capital — Seed
- Suzhou Capital Group — Seed